BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Trial Profile

BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Risankizumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IMMvent
  • Sponsors AbbVie; Boehringer Ingelheim Pharma KG
  • Most Recent Events

    • 26 Oct 2017 According to an AbbVie media release, Kristian Reich, Professor of Dermatology, Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany, is the principal investigator of the study.
    • 26 Oct 2017 Primary endpoint has been met. (Achievement of a static Physician Global Assessment (sPGA) score of clear or almost clear at Week 16), according to an AbbVie media release.
    • 26 Oct 2017 Primary endpoint has been met. (Achievement of 90% reduction from baseline Psoriasis Area and Severity Index (PASI) score (PASI 90) at Week 16), according to an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top